Tumor	0	5	B-Cell
endothelial	6	17	I-Cell
cell	18	22	I-Cell
targeted	23	31	O
cyclic	32	38	B-Drug_or_compound
RGD	39	42	I-Drug_or_compound
-	42	43	I-Drug_or_compound
modified	43	51	I-Drug_or_compound
heparin	52	59	I-Drug_or_compound
derivative	60	70	I-Drug_or_compound
:	70	71	O
inhibition	72	82	O
of	83	85	O
angiogenesis	86	98	O
and	99	102	O
tumor	103	108	B-Pathological_formation
growth	109	115	O
.	115	116	O

PURPOSE	118	125	O
:	125	126	O
We	127	129	O
prepared	130	138	O
tumor	139	144	B-Tissue
endothelium	145	156	I-Tissue
targeted	157	165	O
cRGD	166	170	B-Drug_or_compound
-	170	171	I-Drug_or_compound
modified	171	179	I-Drug_or_compound
heparin	180	187	I-Drug_or_compound
derivative	188	198	I-Drug_or_compound
(	199	200	O
cRGD	200	204	B-Drug_or_compound
-	204	205	I-Drug_or_compound
HL	205	207	I-Drug_or_compound
)	207	208	O
by	209	211	O
coupling	212	220	O
heparin	221	228	B-Drug_or_compound
-	228	229	I-Drug_or_compound
lithocholic	229	240	I-Drug_or_compound
acid	241	245	I-Drug_or_compound
(	246	247	O
HL	247	249	B-Drug_or_compound
)	249	250	O
with	251	255	O
cRGDyK	256	262	B-Drug_or_compound
,	262	263	O
and	264	267	O
evaluated	268	277	O
inhibition	278	288	O
effects	289	296	O
of	297	299	O
cRGD	300	304	B-Drug_or_compound
-	304	305	I-Drug_or_compound
HL	305	307	I-Drug_or_compound
on	308	310	O
angiogenesis	311	323	O
and	324	327	O
tumor	328	333	B-Pathological_formation
growth	334	340	O
.	340	341	O

METHODS	342	349	O
:	349	350	O
To	351	353	O
evaluate	354	362	O
antiangiogenic	363	377	O
activity	378	386	O
of	387	389	O
cRGD	390	394	B-Drug_or_compound
-	394	395	I-Drug_or_compound
HL	395	397	I-Drug_or_compound
,	397	398	O
we	399	401	O
performed	402	411	O
tests	412	417	O
on	418	420	O
endothelial	421	432	B-Cell
cell	433	437	I-Cell
adhesion	438	446	O
and	447	450	O
migration	451	460	O
to	461	463	O
vitronectin	464	475	B-Gene_or_gene_product
,	475	476	O
tube	477	481	B-Tissue
formation	482	491	O
,	491	492	O
binding	493	500	O
affinity	501	509	O
to	510	512	O
purified	513	521	O
alpha	522	527	B-Gene_or_gene_product
(	527	528	I-Gene_or_gene_product
v	528	529	I-Gene_or_gene_product
)	529	530	I-Gene_or_gene_product
beta	530	534	I-Gene_or_gene_product
(	534	535	I-Gene_or_gene_product
3	535	536	I-Gene_or_gene_product
)	536	537	I-Gene_or_gene_product
integrin	538	546	I-Gene_or_gene_product
,	546	547	O
and	548	551	O
in	552	554	O
vivo	555	559	O
Matrigel	560	568	O
plug	569	573	O
assay	574	579	O
.	579	580	O

The	581	584	O
antitumor	585	594	B-Pathological_formation
activity	595	603	O
of	604	606	O
cRGD	607	611	B-Drug_or_compound
-	611	612	I-Drug_or_compound
HL	612	614	I-Drug_or_compound
was	615	618	O
also	619	623	O
evaluated	624	633	O
by	634	636	O
monitoring	637	647	O
tumor	648	653	B-Pathological_formation
growth	654	660	O
and	661	664	O
microvessel	665	676	B-Tissue
formation	677	686	O
in	687	689	O
squamous	690	698	B-Pathological_formation
cell	699	703	I-Pathological_formation
carcinoma	704	713	I-Pathological_formation
(	714	715	I-Pathological_formation
SCC7	715	719	I-Pathological_formation
)	719	720	I-Pathological_formation
tumor	721	726	I-Pathological_formation
.	726	727	O

RESULTS	728	735	O
:	735	736	O
The	737	740	O
cRGD	741	745	B-Drug_or_compound
-	745	746	I-Drug_or_compound
HL	746	748	I-Drug_or_compound
significantly	749	762	O
inhibited	763	772	O
adhesion	773	781	O
and	782	785	O
migration	786	795	O
of	796	798	O
endothelial	799	810	B-Cell
cells	811	816	I-Cell
to	817	819	O
vitronectin	820	831	B-Gene_or_gene_product
,	831	832	O
and	833	836	O
tubular	837	844	B-Tissue
structures	845	855	I-Tissue
of	856	858	O
endothelial	859	870	B-Cell
cells	871	876	I-Cell
.	876	877	O

Compared	878	886	O
to	887	889	O
cRGDyK	890	896	B-Drug_or_compound
and	897	900	O
HL	901	903	B-Drug_or_compound
,	903	904	O
cRGD	905	909	B-Drug_or_compound
-	909	910	I-Drug_or_compound
HL	910	912	I-Drug_or_compound
has	913	916	O
high	917	921	O
binding	922	929	O
affinity	930	938	O
to	939	941	O
purified	942	950	O
alpha	951	956	B-Gene_or_gene_product
(	956	957	I-Gene_or_gene_product
v	957	958	I-Gene_or_gene_product
)	958	959	I-Gene_or_gene_product
beta	959	963	I-Gene_or_gene_product
(	963	964	I-Gene_or_gene_product
3	964	965	I-Gene_or_gene_product
)	965	966	I-Gene_or_gene_product
integrin	967	975	I-Gene_or_gene_product
.	975	976	O

The	977	980	O
enhanced	981	989	O
antiangiogenic	990	1004	O
effect	1005	1011	O
of	1012	1014	O
cRGD	1015	1019	B-Drug_or_compound
-	1019	1020	I-Drug_or_compound
HL	1020	1022	I-Drug_or_compound
was	1023	1026	O
confirmed	1027	1036	O
in	1037	1039	O
Matrigel	1040	1048	O
assay	1049	1054	O
by	1055	1057	O
showing	1058	1065	O
the	1066	1069	O
significant	1070	1081	O
inhibition	1082	1092	O
of	1093	1095	O
bFGF	1096	1100	B-Gene_or_gene_product
-	1100	1101	O
driven	1101	1107	O
angiogenesis	1108	1120	O
and	1121	1124	O
blood	1125	1130	B-Multi-tissue_structure
vessel	1131	1137	I-Multi-tissue_structure
formation	1138	1147	O
.	1147	1148	O

It	1149	1151	O
was	1152	1155	O
thought	1156	1163	O
that	1164	1168	O
potent	1169	1175	O
antiangiogenic	1176	1190	O
effect	1191	1197	O
of	1198	1200	O
cRGD	1201	1205	B-Drug_or_compound
-	1205	1206	I-Drug_or_compound
HL	1206	1208	I-Drug_or_compound
was	1209	1212	O
probably	1213	1221	O
due	1222	1225	O
to	1226	1228	O
the	1229	1232	O
interference	1233	1245	O
of	1246	1248	O
alpha	1249	1254	B-Gene_or_gene_product
(	1254	1255	I-Gene_or_gene_product
v	1255	1256	I-Gene_or_gene_product
)	1256	1257	I-Gene_or_gene_product
beta	1257	1261	I-Gene_or_gene_product
(	1261	1262	I-Gene_or_gene_product
3	1262	1263	I-Gene_or_gene_product
)	1263	1264	I-Gene_or_gene_product
-	1264	1265	O
mediated	1265	1273	O
interaction	1274	1285	O
,	1285	1286	O
resulting	1287	1296	O
in	1297	1299	O
the	1300	1303	O
enhanced	1304	1312	O
antitumoral	1313	1324	O
activity	1325	1333	O
against	1334	1341	O
SCC7	1342	1346	B-Pathological_formation
tumor	1347	1352	I-Pathological_formation
.	1352	1353	O

CONCLUSION	1354	1364	O
:	1364	1365	O
These	1366	1371	O
results	1372	1379	O
demonstrated	1380	1392	O
that	1393	1397	O
cRGD	1398	1402	B-Drug_or_compound
-	1402	1403	I-Drug_or_compound
modified	1403	1411	I-Drug_or_compound
heparin	1412	1419	I-Drug_or_compound
derivative	1420	1430	I-Drug_or_compound
enhanced	1431	1439	O
anti	1440	1444	O
-	1444	1445	O
angiotherapeutic	1445	1461	O
effects	1462	1469	O
against	1470	1477	O
solid	1478	1483	B-Pathological_formation
tumor	1484	1489	I-Pathological_formation
,	1489	1490	O
and	1491	1494	O
therefore	1495	1504	O
,	1504	1505	O
it	1506	1508	O
could	1509	1514	O
be	1515	1517	O
applied	1518	1525	O
to	1526	1528	O
treat	1529	1534	O
various	1535	1542	O
cancers	1543	1550	B-Pathological_formation
and	1551	1554	O
angiogenic	1555	1565	O
diseases	1566	1574	O
as	1575	1577	O
a	1578	1579	O
potent	1580	1586	O
angiogenesis	1587	1599	O
inhibitor	1600	1609	O
.	1609	1610	O

